DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
Human immunodeficiency virus (HIV) protease inhibitors (PIs) are important components of many highly active antiretroviral therapy regimens. However, development of phenotypic and/or genotypic resistance can occur, including cross-resistance to other PIs. Development of resistance takes place because trough levels of free drug are inadequate to suppress preexisting resistant mutant variants and/or to inhibit de novo-generated resistant mutant variants. There is thus a need for new PIs, which are more potent against mutant variants of HIV and show higher levels of free drug at the trough. We have optimized a series of substituted sulfonamides and evaluated the inhibitors against laboratory strains and clinical isolates of HIV type 1 (HIV-1), including viruses with mutations in the protease gene. In addition, serum protein binding was determined to estimate total drug requirements for 90% suppression of virus replication (plasma IC(90)). Two compounds resulting from our studies, designated DPC 681 and DPC 684, are potent and selective inhibitors of HIV protease with IC(90)s for wild-type HIV-1 of 4 to 40 nM. DPC 681 and DPC 684 showed no loss in potency toward recombinant mutant HIVs with the D30N mutation and a fivefold or smaller loss in potency toward mutant variants with three to five amino acid substitutions. A panel of chimeric viruses constructed from clinical samples from patients who failed PI-containing regimens and containing 5 to 11 mutations, including positions 10, 32, 46, 47, 50, 54, 63, 71, 82, 84, and 90 had mean IC(50) values of <20 nM for DPC 681 and DPC 681, respectively. In contrast, marketed PIs had mean IC(50) values ranging from 200 nM (amprenavir) to >900 nM (nelfinavir).
Kaltenbach
R F
RF
Department of Chemistry and Physical Sciences, DuPont Pharmaceuticals Co., Wilmington, Delaware 19880-0336, USA.
Trainor
G
G
Getman
D
D
Harris
G
G
Garber
S
S
Cordova
B
B
Bacheler
L
L
Jeffrey
S
S
Logue
K
K
Cawood
P
P
Klabe
R
R
Diamond
S
S
Davies
M
M
Saye
J
J
Jona
J
J
Erickson-Viitanen
S
S
D000284:Administration, Oral; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D004285:Dogs; D004352:Drug Resistance, Microbial; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011485:Protein Binding; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000494:pharmacology*
D001798:Blood Proteins; C444448:DPC 681; C444449:DPC 684; D017320:HIV Protease Inhibitors; D013449:Sulfonamides